Overview

Antiischemic Effects of Empagliflozin in Diabetic Patients With Refractory Angina

Status:
Completed
Trial end date:
2019-05-23
Target enrollment:
Participant gender:
Summary
this study was aimed to evaluation of antiangial effect of a new fda drug approval on angina in diabetic patient with refractory angina
Phase:
Phase 4
Details
Lead Sponsor:
Isfahan University of Medical Sciences
Treatments:
Empagliflozin